Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

Abstract

Consolidation of first remission with (90)Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high PR-to-CR conversion rates regardless of type of first-line induction treatment.

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

“…61 A radiolabeled form of the antibody, 90Y-ibritumomab tiuxetan (Zevalin, Spectrum), is used in the treatment of indolent NHL [62][63][64] and as consolidation therapy following induction. 65,66 Ocrelizumab. Ocrelizumab (PRO70769, Roche/ Genentech) is a humanized anti-CD20 IgG1 Type I antibody that has been evaluated in a Phase 1/2 study in patients with relapsed/refractory FL and is currently in development for the treatment of multiple sclerosis.…”

Six of 12 Relapsed or Refractory Indolent Lymphoma Patients Treated 10 Years Ago with 131I-Tositumomab Remain in Complete Remission

“…A high efficacy of radioimmunotherapy with 90 Y-ibritumomab has been reported repeatedly (3,8,17), including a report on 5-y relapse-free survival in close to 20% of patients with recurrent disease (20). However, 10-y observations after 90 Y-ibritumomab radioimmunotherapy are not yet available.…”

“…These results compare favorably with long-term observations after 131 I-tositumomab treatment in the literature (9,15) and are similar to the results of combined chemotherapy and radioimmunotherapy in the initial treatment of follicular lymphoma (16). Combined up-front treatment including chemotherapy or rituximabchemotherapy and radioimmunotherapy for consolidation (16,17) and further maintenance immunotherapy might provide optimal patient benefit. The South West Oncology Group (US) phase II trial (NCT00770224) is currently exploring this strategy.…”

Changing therapeutic landscape – The last decade

“…Studies designed to register these drugs for earlier disease phases generally did not use what are now considered best available treatment options, making conclusions on the usefulness of radioimmunotherapy for treatment of newly diagnosed patients or those in first relapse or second remission difficult [13,42].…”